Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tecovirimat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tecovirimat SCHEMBL16177619 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL14601849 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL16177983 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL404743 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL20126651 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL10034023 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL10029251 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL406595 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL21549158 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL30702765 | 0.99 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433868-B2 | Polymorphic forms of ST-246 and methods of preparation | SIGA TECHNOLOGIES, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-20240156782-A1 | POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION | SIGA TECHNOLOGIES, INC. (US) | 2024-05-16 | — | — | US | claimed |
| US-10933050-B2 | Polymorphic forms of ST-246 and methods of preparation | SIGA TECHNOLOGIES INC. (US) | 2021-03-02 | — | — | US | claimed |
| US-10716759-B2 | Rehydration of micronized tecovirimat monohydrate | SIGA TECHNOLOGIES INC. (US) | 2020-07-21 | — | — | US | claimed |
| US-20190343799-A1 | POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION | SIGA TECHNOLOGIES, INC. (US) | 2019-11-14 | — | — | US | claimed |
| US-10406103-B2 | Rehydration of micronized tecovirmimat monohydrate | SIGA TECHNOLOGIES INC. (US) | 2019-09-10 | — | — | US | claimed |
| EP-3416637-A1 | ST-246 ( TECOVIRIMAT MONOHYDRATE) SUSPENSION FORMULATIONS | Siga Technologies, Inc. (US) | 2018-12-26 | — | — | EP | claimed |
| US-20180311213-A1 | POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION | SIGA TECHNOLOGIES, INC. (US) | 2018-11-01 | — | — | US | claimed |
| EP-2549871-B1 | POLYMORPHIC FORM ST-246 AND METHODS OF PREPARATION | SIGA TECH INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-9744154-B2 | Polymorphic forms of ST-246 and methods of preparation | SIGA TECHNOLOGIES, INC. (US) | 2017-08-29 | — | — | US | claimed |
| US-7737168-B2 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-06-15 | — | — | US | claimed |
| EP-2192901-A2 | CHEMICALS, COMPOSITIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2010-06-09 | — | — | EP | claimed |
| EP-2148860-A1 | CHEMICALS, COMPOSITIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2010-02-03 | — | — | EP | claimed |
| WO-2008130348-A1 | CHEMICALS, COMPOSITIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| EP-1638938-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES INC (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2008079159-A2 | CHEMICALS, COMPOSITIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | claimed |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2006-10-19 | — | — | US | claimed |
| EP-1638938-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | Siga Technologies, Inc. (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2004112718-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2004-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10716759-B2 | Rehydration of micronized tecovirimat monohydrate | TSLP, TREH, SLC5A1 | ALDH1A1 2501/4885SMN1; SMN2 1510/4885MEN1 681/4885 |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | ALDH1A1 1899/4885SMN1; SMN2 2395/4885MEN1 4313/4885 |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | ALDH1A1 1899/4885SMN1; SMN2 2395/4885MEN1 4313/4885 |
| US-10406103-B2 | Rehydration of micronized tecovirmimat monohydrate | TSLP, CCL11, THPO | ALDH1A1 3920/4885SMN1; SMN2 978/4885MEN1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.